Fraiser Kansteiner

6 days ago | fiercepharma.com | Fraiser Kansteiner

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its chief markets in Asia. Roche is investing roughly 2.04 billion Chinese yuan ($282 million) to erect a new biomanufacturing hub in Shanghai, China. The plant, which will mark Roche’s second for branded medicines in the country, will mainly be used for domestic production of the eye med Vabysmo, which goes by the commercial moniker Luoshijia in China.

1 week ago | fiercepharma.com | Fraiser Kansteiner

In the wake of mass restructuring efforts across the Department of Health and Human Services, the FDA has missed yet another approval decision target date. GSK had expected to secure an FDA nod for its IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) on Wednesday, but the May 7 deadline has come and gone without a decision from the U.S. regulator. “Based on our latest discussions with the FDA, we continue to expect approval,” a GSK spokesperson said in an email.

1 week ago | fiercepharma.com | Fraiser Kansteiner

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the hybrid generics and innovative medicines giant. As part of a new bid to save roughly $700 million by 2027, Teva will lay off around 8% of its total staff over the same time frame, the company said in an earnings presentation Wednesday.

1 week ago | fiercepharma.com | Fraiser Kansteiner

Monday, Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments in the face of potential pharmaceutical import tariffs. At the same time, however, the CEO took the opportunity to strike back against the Trump administration’s trade policies, federal health layoffs and funding cuts that have dominated the industry’s attention in recent months.

1 week ago | fiercepharma.com | Fraiser Kansteiner

After revealing in February plans to save $2 billion more on top of a previously disclosed cost-cutting initiative, Bristol Myers Squibb is conducting another round of job cuts in the Garden State. BMS is laying off 516 workers who report to the company in Lawrenceville, New Jersey, according to a new Worker Adjustment and Retraining Notification Act (WARN) report filed (PDF) with the state. The move is part of a broader cost-cutting initiative designed to save $2 billion by the end of 2027.